Lv1
40 积分 2025-12-24 加入
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
9个月前
已完结
Semaglutide vs Tirzepatide for Weight Loss in AdultsWith Overweight or Obesity
9个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
9个月前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
9个月前
已完结
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
9个月前
已完结
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
9个月前
已完结
皖公网安备34019202002308
